Prognostic significance of hepatic encephalopathy in patients with cirrhosis treated with current standards of care

被引:0
作者
Anuj Bohra [1 ]
Thomas Worland [1 ,2 ]
Samuel Hui [1 ]
Ryma Terbah [2 ]
Ann Farrell [1 ]
Marcus Robertson [1 ,2 ,3 ]
机构
[1] Department of Gastroenterology,Monash Health  2. Department of Gastroenterology,Austin Health
[2] Department of Medicine,School of Clinical Sciences,Monash University
关键词
Hepatic encephalopathy; Cirrhosis; Portal hypertension; Prognosis; Rifaximin; Lactulose;
D O I
暂无
中图分类号
R473.5 [内科护理学];
学科分类号
1011 ;
摘要
BACKGROUND Hepatic encephalopathy(HE) is a reversible neuropsychiatric complication of liver cirrhosis and occurs in up to 50% of cirrhotic patients. Studies examining the prognostic significance of HE are limited despite the high prevalence in cirrhosis.AIM To define the clinical outcomes of patients after an episode of HE treated with current standards-of-care.METHODS All patients hospitalised with HE requiring Rifaximin to 3 tertiary centres over46-mo(2012–2016) were identified via pharmacy dispensing records. Patients with hepatocellular carcinoma and those prescribed Rifaximin prior to admission were excluded. Medical records were reviewed to determine baseline characteristics and survival. The Kaplan-Meier method was used to calculate survival probability. Univariate survival analysis was performed with variables reaching statistical significance included in a multivariate analysis. The primary outcome was 12-mo mortality following commencement of Rifaximin.RESULTS188 patients were included. Median age was 57 years(IQR 50-65), 71% were male and median model for end stage liver disease and Child Pugh scores were 25(IQR 18-31) and 11(IQR 9-12) respectively. The most common causes of cirrhosis were alcohol(62%), hepatitis C(31%) and non-alcoholic fatty liver disease(20%).A precipitating cause for HE was found in 92% patients with infection(43%), GI bleeding(16%), medication non-compliance(15%) and electrolyte imbalance(14%) the most common. During a mean follow up period of 12 ± 13 mo 107(57%) patients died and 32(17%) received orthotopic liver transplantation. Themost common causes of death were decompensated chronic liver disease(57%)and sepsis(19%). The probability of survival was 44% and 35% at 12-and 24-mo respectively. At multivariate analysis a model for end stage liver disease > 15 and international normalised ratio reached statistical significance in predicting mortality.CONCLUSION Despite advances made in the management of HE patients continue to have poor survival. Thus, in all patients presenting with HE the appropriateness of orthotopic liver transplantation should be considered.
引用
收藏
页码:2221 / 2231
页数:11
相关论文
共 50 条
  • [31] SPECTRUM OF PRECIPITATING FACTORS OF HEPATIC ENCEPHALOPATHY IN PATIENTS WITH LIVER CIRRHOSIS
    Singeap, Ana Maria
    Cuciureanu, T.
    Zenovia, S.
    Girleanu, Irina
    Huiban, Laura
    Muzica, Cristina Maria
    Stanciu, C.
    Trifan, Anca
    [J]. MEDICAL-SURGICAL JOURNAL-REVISTA MEDICO-CHIRURGICALA, 2021, 125 (04): : 492 - 501
  • [32] Comparison of prognostic systems in cirrhotic patients with hepatic encephalopathy
    Tas, Adnan
    Yalcin, Mehmet Suat
    Saritas, Bunyamin
    Kara, Banu
    [J]. TURKISH JOURNAL OF MEDICAL SCIENCES, 2018, 48 (03) : 543 - 547
  • [33] Treatment of hepatic encephalopathy in patients with cirrhosis of the liver
    Ferenci, P
    [J]. DIGESTIVE DISEASES, 1996, 14 : 40 - 52
  • [34] Gut Flora and Hepatic Encephalopathy in Patients with Cirrhosis
    Riordan, Stephen M.
    Williams, Roger
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (12) : 1140 - 1142
  • [35] The Psychometric Hepatic Encephalopathy Syndrome score does not correlate with blood ammonia, endotoxins or markers of inflammation in patients with cirrhosis
    Kimer, Nina
    Gluud, Lise Lotte
    Pedersen, Julie Steen
    Tavenier, Juliette
    Moller, Soren
    Bendtsen, Flemming
    [J]. TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY, 2021, 6
  • [36] Screening for minimal hepatic encephalopathy in patients with cirrhosis by cirrhosis-related symptoms and a history of overt hepatic encephalopathy
    Yoshimura, Emi
    Ichikawa, Tatsuki
    Miyaaki, Hisamitsu
    Taura, Naota
    Miuma, Satoshi
    Shibata, Hidataka
    Honda, Takuya
    Takeshima, Fuminao
    Nakao, Kazuhiko
    [J]. BIOMEDICAL REPORTS, 2016, 5 (02) : 193 - 198
  • [37] Disparities in Mortality and Health Care Utilization for 460,851 Hospitalized Patients with Cirrhosis and Hepatic Encephalopathy
    Harry Trieu
    Arpan Patel
    Christine Wells
    Sammy Saab
    Edward Wolfgang Lee
    [J]. Digestive Diseases and Sciences, 2021, 66 : 2595 - 2602
  • [38] Disparities in Mortality and Health Care Utilization for 460,851 Hospitalized Patients with Cirrhosis and Hepatic Encephalopathy
    Trieu, Harry
    Patel, Arpan
    Wells, Christine
    Saab, Sammy
    Lee, Edward Wolfgang
    [J]. DIGESTIVE DISEASES AND SCIENCES, 2021, 66 (08) : 2595 - 2602
  • [39] Zinc supplementation in patients with cirrhosis and hepatic encephalopathy: a systematic review and meta-analysis
    Shen, Ying-Chi
    Chang, Ya-Hui
    Fang, Ching-Ju
    Lin, Yang-Sheng
    [J]. NUTRITION JOURNAL, 2019, 18 (1)
  • [40] Small Intestinal Bacterial Overgrowth Is a Predictor of Overt Hepatic Encephalopathy in Patients with Liver Cirrhosis
    Sakamaki, Akira
    Yokoyama, Kunihiko
    Yamazaki, Hanako
    Wakabayashi, Takuya
    Kojima, Yuichi
    Tominaga, Kentaro
    Tsuchiya, Atsunori
    Kamimura, Kenya
    Yokoyama, Junji
    Terai, Shuji
    [J]. JOURNAL OF CLINICAL MEDICINE, 2025, 14 (05)